Amitifadine

Drug Profile

Amitifadine

Alternative Names: Amitifadine hydrochloride; DOV-21947; EB-1010

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DOV Pharmaceutical
  • Developer Euthymics Bioscience
  • Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alcoholism; Smoking withdrawal
  • Discontinued Major depressive disorder; Obesity

Most Recent Events

  • 01 Nov 2017 Ethismos Research acquires intellectual property assets of amitifadine from Euthymics Bioscience
  • 21 Sep 2017 Discontinued - Phase-II/III for Major depressive disorder (Second-line therapy or greater) in USA (PO) (Euthymics Bioscience website, September 2017)
  • 21 Sep 2017 Preclinical trials in Alcoholism in USA (PO) before September 2017 (Euthymics Bioscience website, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top